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INTRODUCTION
Alzheimer’s disease (AD) is a slowly progressive disease characterized by impairment of memory
and eventually by disturbances in reasoning, planning, language, and perception. Ageing is the
greatest risk factor for its development but mutations in amyloid precursor protein (APP),
apolipoprotein E (APOE), microtubule-associated protein tau (MAPT) among others, are also a
major factor (Blasko et al., 2004). The symptoms of AD result from neurofibrillary tangles that are
composed of aggregates of hyper-phosphorylated tau protein and an increase in the production
of amyloid-beta (Aβ) protein in the brain that leads to deposits of senile plaques. As such, there
is a worldwide effort to find an effective disease-modifying treatment that can reverse symptoms
and/or delay onset of the disease. Transgenic mouse models exist that mimic a range of AD–related
pathologies, although none of the models fully replicate all pathological features of the human
disease (Birch et al., 2014). Drugs developed using these mouse models have failed in phase III
clinical trials (Mangialasche et al., 2010; Braidy et al., 2012; Saraceno et al., 2013). These failures
question not only our accurate understanding of the disease (Castellani and Perry, 2012) but also
the validity of the animal models upon which the drug discovery efforts are rooted (Windisch, 2014;
Nazem et al., 2015).
Animal models have contributed significantly to our understanding of the underlying
mechanisms of AD. To date, however, these findings have not resulted in target validation in
humans and successful translation to disease-modifying therapies. The Octodon degus (O. degus)
is a model that naturally integrates multiple AD pathological hallmarks like tau fibrilary tangles
and β-amyloid deposits (Inestrosa et al., 2005, 2015; Deacon et al., 2015). The Aβ peptide sequence
in O. degus is 97.5% homologous to the human Aβ peptide sequence (Inestrosa et al., 2005). The
species presents acetylcholine (AChE)-rich pyramidal neurons in their forebrain, which decline
in numbers during the progression to an AD-like behavioral state, similar to that seen in AD
patients (Ardiles et al., 2012). Affected O. degus also present the characteristic medical signs and
symptoms surrounding AD like macular degeneration, diabetes and circadian rhythm dysfunction
(Laurijssens et al., 2013). Behavioral experiments have shown that the O. degus can also present
behavioral deficits and neural alterations in the frontal cortex and aggression similar to those seen
in patients with AD (Tarragon et al., 2013). Most importantly, the O. degus shows a correlation of
expression with human AD- related genes making this model a powerful tool to characterize the
effects of novel treatments for AD and identify new therapeutic targets. Our findings advance the
use of the O. degus as an effective tool for AD research.
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MATERIALS AND METHODS
Animals
In this study O. degus (Rodentia: Octodontidae) were captured
from a natural population in central Chile, 30 km west of
Santiago (Rinconada de Maipú, RM). In this environment, degus
typically breed once per year in late autumn (May-June), with
conceptions in late winter to early spring (September-October).
The animals were captured as juveniles during early austral
summer (November), when degus are 2–3 months old, with
meshmade traps with a Sherman-trap type mechanism. Juveniles
corresponded to individuals weighing 70–130 g (females) or 70–
140 g (males), and hence it is possible to differentiate them
categorically from adults, which weight above 130 g for females,
140 g for males (Ebensperger and Hurtado, 2005; Correa et al.,
2016).
They were housed in standard metal cages 50 × 40 × 35
cm with a layer of wood shaving as bedding and containing a
small metallic box (25 × 15 × 10 cm with a single entrance),
under natural photoperiod (12 h light/dark; starting 7 a.m.) and
in an air-conditioned animal facility at the Faculty of Sciences,
University of Chile (Santiago, Chile). They were fed with a
commercial rodent diet (Prolab RMH 3000, Lab diet). Water and
food were provided ad libitum during the entire experimental
period. Behavioral assessment of a population (N = 84) of 3-years
oldO. deguswas performed using the burrowing test in an earlier
work (Deacon et al., 2015), to address behavioral dysfunctions
in activities of daily living (ADL) (Deacon, 2006, 2014). The
population was divided in terms of burrowing performance into
two groups: poor-burrowers (PB) and good-burrowers (GB).
Brain extract samples were obtained from 8 females (four per
each group). Brain soluble Aβ1−42peptide was determined for
these 8 animals by MALDI-TOF MS as described in earlier
work (Deacon et al., 2015). Samples were classified according to
burrowing performance and brain soluble Aβ1−42 levels. Samples
from four PB animals, with an increased level of soluble brain
Aβ1−42 (AD-like group), and three samples from GB animals
(with soluble levels of Aβ1−42 used as control group) were used
for further analysis. Brain tissues were frozen directly in RNAlater
solution (Ambion) and stored at−80◦C until use. All procedures
of capture, transportation, maintenance and experimentation
followed the recommendations of the ethics committee of the
Faculty of Sciences of the University of Chile, and complied with
Chilean regulations (SAG-Chilean Agriculture and Livestock
Service) as well as recommendations by the Animal Behavior
Society.
Total RNA and mRNA Isolation
For total RNA extraction, PureLinkTM RNA Mini kit (Ambion,
Life Technologies) was used according to the manufacturer’s
instructions. For genomic DNA digestion, RNase-Free DNase
I (Ambion) was used. Total RNA samples were quantified
in a Nanodrop 2000 spectrophotometer and integrity was
evaluated by agarose gels electrophoresis with a standard
protocol. For mRNA isolation from total RNA samples,
MicroPoly(A) Purist kit was used according to themanufacturer’s
instructions. For sizing, quantitation and quality control of
mRNA Bioanalyzer system (Agilent) was used, discarding
samples with an RIN < 7.
RNA-sequencing
RNA-seq was performed at the National Center for Genomics
and Bioinformatics (Santiago, Chile) including library
preparation (using SOLiD Total RNA-seq kit), fragmentation
and PCR enrichment of target mRNA according to strand-
specific protocols. Two batches of paired-end (75 × 35 bp)
library sequencing were done in a SOLiD 5,500 × l system
(Applied Biosystems).
Gene Prediction
We combined both ab initio and evidence-based approaches by
using the Program to Assemble Spliced Alignments (PASA) and
Evidence Modeler (EVM) to de novo annotate protein coding
genes in O. degus genome assembly (v1.0) (Haas, 2003). In total
25,621 transcript models were generated by PASA from an initial
set of 1,767,640 sequences including (1) 26,240 O. degus mRNA
transcripts and (2) 1,741,759 ESTs and mRNA sequences from
four species of rodents: mouse, guinea pig, Chinese hamster and
rat. Transcript sequences for all five species were derived from the
GenBank NCBI databases. We also used >30 million UniRef90
protein clusters and 26,259 highly curated rodent-specific Swiss-
Prot proteins that were split-mapped to the O. degus genome
by using SPALN2 (Iwata and Gotoh, 2012) and EXONERATE
(Slater and Birney, 2005) with mouse-specific parameters. The
protein-coding gene predictions were obtained on the latest
repeat-masked reference assembly of the O. degus genome by
using the existing mammalian-specific parameter files of four
ab initio gene prediction programs: Augustus, Geneid, SGP2,
and SNA (Guigó et al., 1992; Guigo et al., 2003; Parra et al.,
2003; Stanke et al., 2006a,b). For SGP2, TBLASTX (Altschul,
1997) alignments between human (hg38) and O. degus were
additionally used to improve the accuracy of gene predictions
(Table S1). We also used external evidence for Geneid including
PASA-derived introns, while for Augustus we used both PASA-
derived intron and exon hints. Performance of all programs
with and without external evidence was evaluated for accuracy
on an artificial scaffold made up of 238 concatenated O. degus
transcripts taken from the NCBI reference annotation. The
alignments (transcript and protein) and ab initio gene models
were combined into consensus CDS models using Evidence
Modeler (Haas et al., 2008). The initial gene set was filtered to
remove reference gene models supported exclusively by SNAP
ab initio predictions. The single-exon consensus gene models
derived from predictions solely supported by Geneid, SGP2 or
AUGUSTUSwith length<300 nucleotides and an EVM score<5
were also excluded. The weights of each given source were chosen
empirically and based on suggestions contained in the EVM
documentation. The highest weights were given to transcript
alignments, followed by protein alignments and finally ab initio
predictions (Augustus, Geneid, SGP2, and SNAP, Table S2). The
consensus gene models were loaded into the PASA database and
passed through five rounds of annotation updates to add UTRs
and alternative splicing variants (Table S3).
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Functional Annotation
Predicted protein-coding genes in the O. degus genome were
further functionally annotated using an in-house developed,
automatic pipeline. For each protein sequence we assigned
protein signatures, orthology groups, as well as annotated
metabolic pathways and reactions using an orthology-based
approach. In this analysis we used InterProScan v.5 (Zdobnov
and Apweiler, 2001) to scan though all available InterPro
databases, including PANTHER, Pfam, TIGRFAM, HAMAP,
and SUPERFAMILY and to specify different protein coding
signatures in predicted protein coding genes. The protein
signatures (protein families, regions, domains, repeats and sites)
were further employed to investigate the classification and to
assign biological functions to predicted proteins. Blast2GO (Götz
et al., 2008) analysis was used to identify GO terms for the
predicted proteins, while KEGG Automatic Annotation Server
(KAAS) (Moriya et al., 2007) was employed to compare protein
sequences against KEGG (Kanehisa et al., 2012, 2014) orthology
(KO). In this analysis, KASS applied its bi-directional best hit
(BBH) method in homology search against a representative
gene set from 33 different species, including Mus musculus and
Cricetulus griseus. KO identifiers were then used to retrieve
the KEGG relevant functional annotation, such as metabolic
pathways and external database references. In addition, we
assigned the NCBI gene names from the O. degus reference
NCBI annotation (ref_OctDeg1.0) to the predicted genes. This
was done by taking NCBI gene names from the corresponding,
NCBI annotated proteins, showing full sequence similarity. The
sequence similarity was measured by assigning SHA1 checksum
to each protein in both proteomes, followed by comparing those
sums.
Mapping O. degus Brain RNA-Seq Samples
The O. degus RNA Sequences were aligned to a reference
transcriptome obtained from the masked primary genome
assembly version 1.0 (WGS Project: AJSA01) and the EVM-based
genome annotation. The transcriptome sequence was prepared
using RSEM version 1.2.12 (Li and Dewey, 2011) and projected
from base space to SOLiD color space using SHRiMP version
2.2.3 (Rumble et al., 2009). The latter program was also employed
to align SOLiD 75 × 35 bp pair-end sequenced reads to the
reference transcriptome according to the following non-default
parameters: -h 80% -o 10 -p opp-in –no-half-paired.
Mapping Human Brain RNA-Seq Samples
The RNA-seq data set consisting of 6 human brain samples
(3 AD subjects and 3 controls, University of Kentucky
brain bank) was derived from the National Center for
Biotechnology Information Sequence Read Archive database
(ncbi.nlm.nih.gov/sra, accession no. SRA060572). Next, pair-
end reads were mapped to the human reference transcriptome
using our in-house pipeline that combines STARv.2.4.0.1 (Dobin
et al., 2013) and RSEM version 1.2.12 (Table S4). The reference
transcriptome was obtained from human reference genome
hg38 and GENCODE v21 (Harrow et al., 2012) as a reference
annotation.
Expression Profiling of Human and
O. degus Brain Samples
The number of reads mapped to each gene was calculated
using SAMtools (Li et al., 2009). The statistical significance
of expression profile for each gene between two groups was
determined using edgeR, an open source R/Bioconductor
package (Robinson et al., 2010). In this study, to estimate the
significance of gene expression difference between AD or AD-
like (PB) subjects and human controls or O. degus (GB) controls,
the absolute value of log2 Ratio (logFC ≥ 1), log read count per
million reads (logCPM > 1) and FDR < 0.05 were used as a
criterion. Raw gene reads counts were also normalized to RPKM
values (reads per kilobase per million mapped reads) using the
RPKM formula described by Mortazavi et al. (2008).
GO Enrichment Analysis for Differentially
Expressed Genes
Functional enrichment analysis forO. deguswas performed using
Fisher’s exact test implemented in R programming language. The
GO enrichment analysis for human was also done using R. The
GOstats package was used to detect the significantly enriched GO
terms for DEGs, which were compared to the full GENCODE 21
gene set. For both species, we further analyzed top 20 GO terms
ranked by p-value with p < 0.05.
RESULTS
Gene Prediction and Functional Annotation
With the aim to enrich the current version of O. degus
genome annotation with the new data obtained in this study,
we performed de novo protein coding gene annotation. Our
Evidence-Modeler (EVM) based annotation of repeat-mask O.
degus genome (v1.0) resulted in prediction of 31,739 protein-
coding genes, corresponding to 36,866 predicted transcripts
and 36,575 proteins. The comparison of EVM-based and NCBI
reference annotation revealed that the number of protein coding
genes increased by 1.52-fold from 20,779 (NCBI) to 31,739
(EVM-based). Similar 1.40-fold change was reported for protein
coding transcripts (26,248 for NCBI and 36,866 for EVM-based
annotation) (Table S3).
Each protein sequence was functionally annotated using the
in house automated pipeline. Annotation features were assigned
to a total of 35,618 (97%) proteins, 30,661 (97%) genes), of
these 29,847 (82%) of the proteins were assigned some GO
terms (Tables S5, S6, Figures S1, S2). This functional annotation,
including GO terms and KEGG orthology groups, allowed us to
perform enrichment analysis for genes of interest.
The Brain Transcriptome of AD-like
O. degus
After mapping the reads to the O. degus genome, we performed
pairwise comparisons to measure the gene expression level
differences between AD-like subjects and controls. As a result
54 DEGs were identified between those two groups. Statistical
analysis revealed 29 genes to be up- and 25 to be down-regulated
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FIGURE 1 | (A) Expression (FPKM values) analysis of 54 differentially expressed genes in PB group compared to GB group with two-way clustering applied. (B)
Complete list of KEGG pathways corresponding to 29 up- and 25 down-regulated genes between PB and GB. Columns A and C: KEGG entry for up- and
down-regulated genes, Columns B and D: Pathway names for up- and down-regulated genes. (C) Comparison of differentially expressed genes in PB vs. GB and
AD-related human genes. Overall AD-correlated genes and AD-correlated genes with incipient AD stage.
in our study (Table S10). The relative change in gene expression
levels across AD-like and control samples is shown in Figure 1A.
To determine the function of DEGs, a Gene Ontology
(GO) enrichment analysis was performed (Table S7). The
up-regulated genes were enriched notably in chromosome
related processes, which include chromosome condensation and
chromosome organization. GO results showed also that up-
regulated genes were largely involved in amine biosynthesis,
in particular biosynthesis of polyamines. In contrast, most
down-regulated genes were mainly engaged in ion homeostasis
related processes, such as sodium-independent organic anion
transport, hyperosmotic salinity response or regulation of cellular
pH reduction. To fully determine which pathways could be
directly affected in AD, DEGs were analyzed using KEGG
PATHWAY Database (Braidy et al., 2012). The up-regulated
genes were observed to be mainly part of signaling pathways
including MAPK, Rap1, Ras and neurotransmission (cholinergic
synapse), while down-regulated genes were part of pathways
related to AD, Parkinson’s disease and Huntington’s disease
(Figure 1B). Specifically down-regulation of COX8A gene. The
COX8A encodes subunit VIIIA of cytochrome c oxidase, a
crucial element for the formation of complex IV, which is a
part of electron transport chain (ETC) in mitochondria. This is
consistent with previously published data, as AD has been already
linked to low activity of brain cytochrome c oxidase (Alleyne
et al., 2011; Readnower et al., 2011). A substantial number of
other down-regulated genes were also found to participate in
different metabolic pathways.
Comparison of Human and O. degus
AD-like Brain Transcriptomes
To gain insights to how O. degus could be employed as a natural
model for studying the pathogenesis of AD, a human AD brain
transcriptome was analyzed using RNA-seq data derived from
hippocampus tissue of AD subjects and controls (Bai et al.,
2013). Analysis of DEGs resulted in identification of 1,572 up
and 1,391 down-regulated genes, which were further compared
to DEGs identified for O. degus (Table S8). This comparison
revealed overlap between seven genes, including FGF9, WISP1
and CPNE7 that are known to be linked with AD. Both FGF9
and WISP1 were observed to show the opposite expression
changes for human and O. degus, while the altered expression
of CPNE7 was consistent between both species. Other common
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DEGs included one up-regulated gene: ITGBL1, and two down-
regulated genes: C1orf95, LRRC55, as well as IL1RAPL2, which
was down-regulated in O. degus brain and up-regulated in
human hippocampus. To further compare human and O. degus
AD-like brain transcriptomes, GO enrichment was employed.
GO analysis revealed that that up-regulated genes for human
were mainly involved in system and tissue development, in
particular circulatory system and vasculature development (Table
S9). This is to some extend consistent with biological processes
described forO. degus up-regulated genes, asmajority of enriched
terms were biosynthesis related. Down-regulated genes were
significantly enriched in neurological processes including signal
transduction and neurogenesis. Similar to O. degus, AD affects
glutamate secretion and glutamate receptor signaling pathways
in human brain. Interestingly, genes involved in regulation of ion
transport was also affected, supporting the relationship between
cellular stress signals and AD.
Comparison of O. degus DEGs and Human
AD-related Genes
To investigate the potential role of O. degus DEGs in human
AD progression, we compared our results to a set of AD-related
genes, generated using Affymetrix expression microarrays across
different stages of human AD: incipient, moderate and severe,
as well as control samples (Blalock et al., 2011). AD-related
genes were defined as genes, whose expression was positively
or negatively correlated with results of MiniMental Status
Examination (MMSE) and neurofibrillary tangles (NFT) counts
across three AD categories (Blalock et al., 2004). Interestingly,
five O. degus DEGs could be linked to AD-related genes in
all subjects (overall correlation) this included COX16, APOC1,
ITGBL1, FGF9, and AMD1. All five DEGs correlated with MMSE
scores, while three: ITGBL1, FGF9, and AMD1 were both MMSE
and NFT-correlated. However, only AMD1 showed a similar
correlation with incipient AD (Figure 1C).
DISCUSSION
The purpose of the present study was to characterize the brain
transcriptome of the O. degus to support its use as a natural
model of AD, by comparing the transcriptomes of AD-like and
healthy O. degus. This study is, to the best of our knowledge,
the first report ofO. degus brain whole transcriptome sequencing
(RNA-seq). Our results revealed in O. degus a number of genes
previously implicated in AD and related disorders indicating that
this model is a suitable alternative to transgenic mice models
for AD research. Because the AD-pathology can vary widely
with animal age we carefully matched control and AD-like
groups. Animals aged 3 years have optimal AD-like pathology
development namely, the presence of beta-amyloid deposits as
has been previously reported (Inestrosa et al., 2005; Ardiles et al.,
2012; Deacon et al., 2015). This allowed for an acceptable signal
dynamic for the experimental analysis. The sample size used for
this study was calculated on the magnitude of the biological effect
and the inherent variability of the target being measured, in this
case the presence or absence of beta-amyloid deposits. We also
considered the variability in the behavioral measures, which as
previously reported (Deacon et al., 2015) showed clustering in
two cohort of animals, AD-like and controls in the tests of daily
living.
This work has identified up-regulated genes involved in AD
including the CHRNA6 gene, which encodes a sub-type of
neuronal nicotinic acetylcholine receptor widely associated to
AD, which are mostly linked to Aβ aggregation theory and
that was found previously affected in AD patients (Lombardo
and Maskos, 2015). Another DEG AMD1 (which encodes an
intermediate enzyme relevant to the polyamine biosynthesis)
has an altered activity in AD and has also been implicated in
schizophrenia and mood disorders, and was found up-regulated
in affected AD-like O. degus (Morrison et al., 1993; Fiori and
Turecki, 2008). The down-regulated genes found in the brains of
AD-like O. degus included WNT1 inducible signaling pathway
protein 1 (WISP1) (Varela-Nallar and Inestrosa, 2013). This
gene previously implicated in neurodegeneration by regulation
of mitochondrial signaling and apoptosis is a downstream
target in the Wnt1 signaling pathway (Wang et al., 2012).
Wnt signaling that involves Wnt1 and WISP1 is becoming
recognized as a vital neuroprotective component during AD.
WISP1 stops p53 mediated DNA damage and apoptosis offering
neuronal protection by blocking cytochrome c release (Su et al.,
2008; Wang et al., 2012). Mitochondrial-related genes were also
found to be differentially expressed in AD-like O. degus brains,
including the Cytochrome C Oxidase Subunit 8A (COX8A)
that has been associated with the reduction of neuronal energy
metabolism and mitochondrial dysfunction observed in AD
patients by the inhibition of COX activity as a result of binding
to Aβ-subunits (Lustbader et al., 2004; Liang et al., 2008).
The comparison of human and O. degus AD-like brain
transcriptomes, revealed seven common genes that were
deregulated. This included fibroblast growth factor 9 (FGF9),
WISP1 and Copine VII (CPNE7). Interestingly, the FGF9 gene
is known to be related to the MAPK pathway affected in AD
patients (Antonell et al., 2013), and is one of the therapeutic
targets currently used in AD treatment (Zhang et al., 2014).
Retinal abnormalities have also been reported to be associated
to AD (Berisha et al., 2007). O. degus naturally develops
cataracts, an eye dysfunction linked to neurodegeneration
(Inestrosa et al., 2005, 2015; Braidy et al., 2015; Szabadfi
et al., 2015). Our study revealed deregulated expression of
two genes: FRMD7 and ADAMTS9, which were previously
associated to retinal abnormalities. The FRMD7 gene plays role
in retinal and neurite development, as well as in the neuronal
outgrowth. It was also connected to X-linked infantile nystagmus,
a disease characterized by abnormal eye function (Betts-
Henderson et al., 2010). The ADAMTS9 gene is also known
to be involved in abnormal eye development. Extracellular
matrix is a key mediator in the pathogenesis of age related
macular degeneration and includes ADAMTS9. ADAMTS9
activates AKT promoting photoreceptor degeneration and
consequently membrane thickening and damage of retinal
pigmentary cells. Moreover regulation of mTOR by ADAMTS9
leads to angiogenesis via VEGF A and TSP-1 this way
regulating angiogenesis in the eye (Wight, 2005; Parry et al.,
2009). Moreover, the activity disorders of ADAMTS9 regulation
of the AKT/mTOR pathway leads to glycolysis and glucose
Frontiers in Aging Neuroscience | www.frontiersin.org 5 March 2017 | Volume 9 | Article 64
Altimiras et al. Brain Transcriptome of Octodon Degus
uptake by increasing hypoxia-inducible factor (HIF)-1α (HIF1A)
also been linked to AD (Avramovich-Tirosh et al., 2010). In
humans, an ADAMTS9 gene variant is associated with type 2
diabetes (T2DM) is most frequently linked with aging, cognitive
impairment, AD-associated neuronal APP-Aβ deposits (de la
Monte andWands, 2005). In relation to these results, theO. degus
has insulin resistance and naturally develops type 2 diabetes and
associated cataracts when fed with a diet high in glucose (Datiles
and Fukui, 1989).
We have also identified APOC-I (apolipoprotein C-I) to
be deregulated in AD-like O. degus brain samples. Notably,
APOC-I is part of the APOE/C-I/C-IV/C-II gene cluster on the
chromosome 19 (Smit et al., 1988) and APOE modulates its
expression. This gene encodes a small apolipoprotein that is
associated with Aβ plaques (Kamino et al., 1996). APOC-I plays a
critical role in CNS homeostasis, since altered expression impairs
memory (Abildayeva et al., 2008). Moreover, is to be highlighted
that APOC-I co-localizes with Aβ plaques in the brain in AD
(Abildayeva et al., 2008).
The pathogenic mechanism resulting in the onset and
progression of neurodegenerative diseases like AD is often
associated with genetic variants and mutations and interactions
with environmental impacts, lifestyle risk factors, and slowly
evolving molecular changes due to aging (Jicha and Carr, 2010;
Duchen, 2012). Thus, a number of AD research avenues could be
investigated in this model other than RNA analysis. For example
post-translationally through modification of protein residues like
phosphorylation.
In this study we focused in whole brain, so studies of
additional brain regions are needed and may point to different
genes and additional pathways. The RNA-seq uncoveredmultiple
DE transcripts, several of these are novel and some have been
previously implicated in AD like WISP1 and APOC1. Being
the present work a pilot study we have probably uncovered
only a fraction of what these data may reveal about this model
and its link with AD supporting further work with this species.
Future work is underway in our laboratory to elucidate the
characterization of global gene expression of young and old O.
degus by analysing tissue from different brain areas. To our
knowledge this is the first O. degus brain transcriptome study.
Salazar et al. (2016), compare the sequences of genes in relation
to AD using published data from O. degus, human and other
rodents. They analyzed tau, APP, Apolipoprotein E (APOE),
Presenilin 1 (Psen1), and Aβ-peptide sequences in correlation
with specific human variants associated with AD. Their findings
revealed that O. degus have the arginine substitution present
in the ApoE4 pathogenic human allele; Psen1 gene showed a
greater relatedness between the isoforms of human, degus, guinea
pig, and mole rat, compared to those of others rodents such
the rat, and also described that O. degus Aβ-peptide sequence
presents high homology with the human protein, differing in
only one amino acid (Salazar et al., 2016). Furthermore, Deacon
et al. (2015) shows that AD-like O. degus have high levels
of Aβ-peptide aggregates, APP, TNF-a, IL-6, IFN-a, and the
oxidative stress marker NFE2L2 when compared to healthy
control O. degus, suggesting that AD-like O. degus present
increased inflammation as is observed in human AD patients
(Deacon et al., 2015). Overall the study of others and the
present explorative transcriptome analysis revealed that the AD-
like O. degus shares common affected genes with those have
been implicated in human AD and therefore provides further
characterization of the O. degus as a relevant natural model.
O. degus shows a correlation of expression with human AD-
related genes making this model a powerful preclinical tool to
characterize target effects of novel therapeutics in AD. This study
provides strong evidence to support the O. degus as a valuable
natural model for preclinical work in AD research.
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